Find in Library

The emerging upsurge of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has resulted in a global pandemic which originated in Wuhan city, China. The complicated virology of SARS CoV-2 makes it difficult to evaluate the therapeutic management for this infection. Drug repurposing is been considered in the management of novel coronavirus. Sarilumab, a monoclonal antibody, is being considered in the management of SARS CoV-2 infection, because it binds to both membrane-bound and soluble human interleukin 6 (IL-6) Ra, thereby blocking both IL-6 canonical and trans-signalling pathways. In this study, we tried to evaluate the reasons why Sarilumab is a not suitable option for treating novel coronavirus.